Yiwen Li Selected Research

IMC-EB10

2/2010	Targeting FMS-related tyrosine kinase receptor 3 with the human immunoglobulin G1 monoclonal antibody IMC-EB10.
5/2006	IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples.
2/2005	Inhibitory anti-FLT3 antibodies are capable of mediating antibody-dependent cell-mediated cytotoxicity and reducing engraftment of acute myelogenous leukemia blasts in nonobese diabetic/severe combined immunodeficient mice.
8/2004	Suppression of leukemia expressing wild-type or ITD-mutant FLT3 receptor by a fully human anti-FLT3 neutralizing antibody.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yiwen Li Research Topics

Disease

27	Neoplasms (Cancer) 01/2022 - 06/2002
12	Fibrosis (Cirrhosis) 05/2019 - 05/2005
10	Infections 04/2021 - 01/2019
7	Leukemia 02/2010 - 01/2004
7	Heart Failure 03/2009 - 09/2004
6	Myocardial Infarction 10/2015 - 01/2006
5	Neoplasm Metastasis (Metastasis) 01/2022 - 06/2002
5	Ventricular Remodeling 05/2009 - 05/2003
5	Infarction (Infarctions) 03/2009 - 05/2005
5	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 03/2007 - 01/2004
4	Inflammation (Inflammations) 11/2019 - 09/2006
4	Cicatrix (Scar) 03/2009 - 01/2006
3	Wounds and Injuries (Trauma) 08/2021 - 01/2020
3	Acute Kidney Injury (Acute Renal Failure) 08/2021 - 11/2019
3	Cardiomyopathies (Cardiomyopathy) 01/2021 - 01/2006
3	IGA Glomerulonephritis (IGA Nephropathy) 01/2020 - 01/2017
3	Hematologic Neoplasms (Hematological Malignancy) 02/2010 - 08/2005
3	Hypertrophy 03/2007 - 01/2006
2	Diabetes Mellitus 10/2022 - 01/2019
2	Kidney Diseases (Kidney Disease) 10/2022 - 01/2020
2	Sarcopenia 02/2022 - 01/2021
2	Ulcerative Colitis 12/2021 - 11/2021
2	Cardiac Arrhythmias (Arrythmia) 01/2021 - 10/2018
2	Breast Neoplasms (Breast Cancer) 12/2020 - 04/2020
2	Hypertension (High Blood Pressure) 01/2020 - 11/2019
2	Epstein-Barr Virus Infections 01/2020 - 01/2018
2	Type 2 Diabetes Mellitus (MODY) 01/2019 - 10/2018
2	Hypoxia (Hypoxemia) 01/2018 - 01/2018
2	Ischemia 10/2017 - 02/2017
2	Edema (Dropsy) 06/2017 - 12/2016
2	Hematuria 06/2017 - 12/2016
2	Brain Injuries (Brain Injury) 02/2017 - 08/2016
2	Choroidal Neovascularization 01/2014 - 11/2010
2	Retinal Degeneration 03/2011 - 03/2010
2	Atrophy 05/2007 - 01/2006
1	Body Weight (Weight, Body) 01/2022
1	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2022
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2022

Drug/Important Bio-Agent (IBA)

9	Proteins (Proteins, Gene)FDA Link 12/2021 - 01/2006
6	Biological ProductsIBA 01/2022 - 06/2006
6	CytokinesIBA 01/2014 - 09/2006
6	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 03/2009 - 01/2006
5	KATP ChannelsIBA 01/2021 - 10/2017
5	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2018 - 06/2002
5	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 02/2010 - 06/2002
4	CreatinineIBA 01/2021 - 12/2016
4	EnzymesIBA 01/2020 - 08/2004
4	AntibodiesIBA 01/2018 - 09/2004
4	IMC-EB10IBA 02/2010 - 08/2004
3	Tacrolimus (Prograf)FDA LinkGeneric 10/2022 - 06/2018
3	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2020
3	Pharmaceutical PreparationsIBA 01/2022 - 11/2018
3	Therapeutic UsesIBA 01/2022 - 03/2021
3	AntioxidantsIBA 11/2021 - 01/2020
3	Interleukin-6 (Interleukin 6)IBA 01/2021 - 09/2004
3	PolymersIBA 12/2020 - 10/2015
3	Antiviral Agents (Antivirals)IBA 01/2020 - 01/2018
3	Melanins (Melanin)IBA 11/2019 - 06/2017
3	LigandsIBA 01/2018 - 11/2010
3	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 09/2004 - 06/2002
2	Cyclosporine (Ciclosporin)FDA LinkGeneric 10/2022 - 06/2018
2	ChemokinesIBA 01/2022 - 01/2020
2	CatalaseIBA 12/2021 - 01/2020
2	SaporinsIBA 12/2021 - 12/2020
2	Reactive Oxygen Species (Oxygen Radicals)IBA 08/2021 - 03/2021
2	HydrogelsIBA 04/2021 - 01/2020
2	MetalsIBA 01/2021 - 01/2020
2	ChromatinIBA 01/2021 - 06/2002
2	Free RadicalsIBA 01/2020 - 01/2019
2	CurcuminIBA 12/2019 - 01/2017
2	polydopamineIBA 11/2019 - 10/2017
2	MicellesIBA 01/2019 - 11/2017
2	VaccinesIBA 01/2018 - 12/2003
2	Serum AlbuminIBA 06/2017 - 12/2016
2	Oxygen (Dioxygen)IBA 02/2017 - 01/2014
2	Matrix Metalloproteinases (MMPs)IBA 10/2015 - 05/2009
2	Ciliary Neurotrophic Factor (CNTF)IBA 01/2014 - 03/2010
2	Oncostatin MIBA 01/2014 - 03/2011
2	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 09/2013 - 05/2003
2	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 11/2010 - 06/2002
2	Transforming Growth Factor beta (TGF-beta)IBA 05/2009 - 05/2005
2	Doxorubicin (Adriamycin)FDA LinkGeneric 05/2007 - 01/2006
2	Myosin Heavy Chains (Myosin Heavy Chain)IBA 05/2007 - 01/2006
2	DesminIBA 05/2007 - 01/2006
2	Type 1 Angiotensin ReceptorIBA 05/2007 - 03/2007
2	Troponin IIBA 05/2007 - 01/2006
2	Fas Ligand Protein (Fas Ligand)IBA 05/2007 - 09/2004
2	Monoclonal AntibodiesIBA 03/2007 - 05/2006
2	Immunoglobulin G (IgG)IBA 09/2006 - 08/2004
2	Erythropoietin FDA Link 09/2006 - 01/2006
1	GlucocorticoidsIBA 10/2022
1	Vasoactive Intestinal Peptide (VIP (Vasoactive Intestinal Peptide))IBA 01/2022
1	NeuropeptidesIBA 01/2022
1	Sodium Glutamate (Accent)IBA 01/2022
1	Immune Checkpoint InhibitorsIBA 01/2022

Therapy/Procedure

16	Therapeutics 08/2021 - 05/2005
4	Renal Dialysis (Hemodialysis) 02/2022 - 11/2019
4	Immunotherapy 01/2022 - 12/2003
3	Photothermal Therapy 11/2019 - 10/2017
2	Nephrectomy 05/2009 - 03/2007